BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 15209628)

  • 1. Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease.
    Yeon JE; Choi KM; Baik SH; Kim KO; Lim HJ; Park KH; Kim JY; Park JJ; Kim JS; Bak YT; Byun KS; Lee CH
    J Gastroenterol Hepatol; 2004 Jul; 19(7):799-804. PubMed ID: 15209628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
    Seo YS; Kim JH; Jo NY; Choi KM; Baik SH; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH; Kim A; Yeon JE
    J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease.
    Nakamuta M; Kohjima M; Morizono S; Kotoh K; Yoshimoto T; Miyagi I; Enjoji M
    Int J Mol Med; 2005 Oct; 16(4):631-5. PubMed ID: 16142397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD.
    Zheng L; Lv GC; Sheng J; Yang YD
    J Gastroenterol Hepatol; 2010 Jan; 25(1):156-63. PubMed ID: 19780876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential induction of genes in liver and brown adipose tissue regulated by peroxisome proliferator-activated receptor-alpha during fasting and cold exposure in acyl-CoA dehydrogenase-deficient mice.
    Goetzman ES; Tian L; Wood PA
    Mol Genet Metab; 2005 Jan; 84(1):39-47. PubMed ID: 15639194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor alpha-responsive genes induced in the newborn but not prenatal liver of peroxisomal fatty acyl-CoA oxidase null mice.
    Cook WS; Jain S; Jia Y; Cao WQ; Yeldandi AV; Reddy JK; Rao MS
    Exp Cell Res; 2001 Aug; 268(1):70-6. PubMed ID: 11461119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of bicyclol on tetracycline-induced fatty liver in mice.
    Yu HY; Wang BL; Zhao J; Yao XM; Gu Y; Li Y
    Toxicology; 2009 Jul; 261(3):112-8. PubMed ID: 19427351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection.
    de Gottardi A; Pazienza V; Pugnale P; Bruttin F; Rubbia-Brandt L; Juge-Aubry CE; Meier CA; Hadengue A; Negro F
    Aliment Pharmacol Ther; 2006 Jan; 23(1):107-14. PubMed ID: 16393287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
    Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
    Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased expression of peroxisome proliferator-activated receptor alpha and liver fatty acid binding protein after partial hepatectomy of rats and mice.
    Skrtic S; Carlsson L; Ljungberg A; Lindén D; Michalik L; Wahli W; Oscarsson J
    Liver Int; 2005 Feb; 25(1):33-40. PubMed ID: 15698396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of differences in fatty acid metabolism between obese and non-obese patients with non-alcoholic fatty liver disease.
    Nakamuta M; Kohjima M; Higuchi N; Kato M; Kotoh K; Yoshimoto T; Yada M; Yada R; Takemoto R; Fukuizumi K; Harada N; Taketomi A; Maehara Y; Nakashima M; Enjoji M
    Int J Mol Med; 2008 Nov; 22(5):663-7. PubMed ID: 18949388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic expression of hepatic thioredoxin mRNA in rats with non-alcoholic fatty liver disease.
    Duan XY; Zhao HP; Fan JG
    J Dig Dis; 2010 Apr; 11(2):94-100. PubMed ID: 20402835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.
    Harano Y; Yasui K; Toyama T; Nakajima T; Mitsuyoshi H; Mimani M; Hirasawa T; Itoh Y; Okanoue T
    Liver Int; 2006 Jun; 26(5):613-20. PubMed ID: 16762007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in expression levels of genes involved in fatty acid metabolism: upregulation of all three members of the PPAR family (alpha, gamma, delta) and the newly described adiponectin receptor 2, but not adiponectin receptor 1 during neonatal cardiac development of the rat.
    Steinmetz M; Quentin T; Poppe A; Paul T; Jux C
    Basic Res Cardiol; 2005 May; 100(3):263-9. PubMed ID: 15754086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased peroxisome proliferator-activated receptor alpha gene expression is associated with dyslipidemia in a rat model of chronic renal failure.
    Mori Y; Hirano T; Nagashima M; Shiraishi Y; Fukui T; Adachi M
    Metabolism; 2007 Dec; 56(12):1714-8. PubMed ID: 17998026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docosahexaenoic acid membrane content and mRNA expression of acyl-CoA oxidase and of peroxisome proliferator-activated receptor-delta are modulated in Y79 retinoblastoma cells differently by low and high doses of alpha-linolenic acid.
    Langelier B; Furet JP; Perruchot MH; Alessandri JM
    J Neurosci Res; 2003 Oct; 74(1):134-41. PubMed ID: 13130515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation.
    Larter CZ; Yeh MM; Cheng J; Williams J; Brown S; dela Pena A; Bell-Anderson KS; Farrell GC
    J Gastroenterol Hepatol; 2008 Feb; 23(2):267-75. PubMed ID: 17868330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of medium- and long-chain fatty acid diets on PPAR and SREBP-1 expression and glucose homeostasis in ACBP-overexpressing transgenic rats.
    Oikari S; Ahtialansaari T; Huotari A; Kiehne K; Fölsch UR; Wolffram S; Jänne J; Alhonen L; Herzig KH
    Acta Physiol (Oxf); 2008 Sep; 194(1):57-65. PubMed ID: 18394026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.
    Kurita S; Takamura T; Ota T; Matsuzawa-Nagata N; Kita Y; Uno M; Nabemoto S; Ishikura K; Misu H; Ando H; Zen Y; Nakanuma Y; Kaneko S
    Eur J Pharmacol; 2008 Jul; 588(2-3):316-24. PubMed ID: 18501344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional networks in a rat model for nonalcoholic fatty liver disease: a microarray analysis.
    Sharma MR; Polavarapu R; Roseman D; Patel V; Eaton E; Kishor PB; Nanji AA
    Exp Mol Pathol; 2006 Dec; 81(3):202-10. PubMed ID: 16949573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.